This story originally ran on March 18.
OriGene Technologies this week announced that it has raised $16 million in its completed Series B financing round.
The proceeds will be used to continue building the company's TrueMab monoclonal antibody collection. In a statement, OriGene said that it aims to build a monoclonal antibody collection that will cover the entire human genome of about 20,000 genes or most of the human proteome.
"The funding will propel us closer to meeting our goal," Wei-Wu He, OriGene's chairman and CEO, said.